Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 5Neoplasms 3Ovarian Neoplasms 2Solid Tumors 1Solid Cancers 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 6Cisplatin 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiotherapy 3Radiation 3Nivolumab 3Fluorouracil 3Biopsy 3Surveys and Questionnaires 2Radiosurgery 2Paclitaxel 2Chemoradiotherapy 2Cetuximab 22-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 2zimberelimab 1toripalimab 1temsirolimus 1peposertib 1nabiximols 1motexafin gadolinium 1mogamulizumab 1ipatasertib 1dl1520 1camrelizumab 1brodalumab 1belinostat 1apatinib 1advexin 1Valproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mouth Neoplasms × ipatasertib × Clear all
NCT05172245 2026-05-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
46 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡